Development of new cancer therapeutic agents targeting mitosis
Author:
Affiliation:
1. Array BioPharma, Inc., 3200 Walnut Street, Boulder, CO 80301, USA.
2. Myriad Pharmaceuticals, 320 Wakara Way, Salt Lake City, UT 84103, USA.
Publisher
Informa Healthcare
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1517/13543784.15.11.1411
Reference125 articles.
1. Tubulin-targeting agents
2. Current State of the Art of New Tubulin Inhibitors in the Clinic
3. Review: Tubulin Function, Action of Antitubulin Drugs, and New Drug Development
Cited by 41 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. NAT10 regulates mitotic cell fate by acetylating Eg5 to control bipolar spindle assembly and chromosome segregation;Cell Death & Differentiation;2022-02-24
2. Design concepts of half-sandwich organoruthenium anticancer agents based on bidentate bioactive ligands;Coordination Chemistry Reviews;2021-10
3. Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma;Cells;2021-07-05
4. A recent development of new therapeutic agents and novel drug targets for cancer treatment;SAGE Open Medicine;2021-01
5. Why Great Mitotic Inhibitors Make Poor Cancer Drugs;Trends in Cancer;2020-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3